stoxline Quote Chart Rank Option Currency Glossary
  
Janux Therapeutics, Inc. (JANX)
37.65  -0.27 (-0.71%)    03-28 16:00
Open: 38.35
High: 39.2289
Volume: 385,272
  
Pre. Close: 37.92
Low: 36.95
Market Cap: 1,945(M)
Technical analysis
2024-03-28 4:52:24 PM
Short term     
Mid term     
Targets 6-month :  68.55 1-year :  80.07
Resists First :  58.69 Second :  68.55
Pivot price 38.97
Supports First :  31.49 Second :  14.68
MAs MA(5) :  38.49 MA(20) :  40.04
MA(100) :  16.82 MA(250) :  13.76
MACD MACD :  3.5 Signal :  4.8
%K %D K(14,3) :  25.9 D(3) :  26.5
RSI RSI(14): 58.7
52-week High :  58.69 Low :  5.65
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ JANX ] has closed above bottom band by 6.2%. Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 39.3 - 39.53 39.53 - 39.77
Low: 36.35 - 36.59 36.59 - 36.84
Close: 37.19 - 37.61 37.61 - 38.07
Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Headline News

Thu, 28 Mar 2024
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Wed, 27 Mar 2024
Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.3% - MarketBeat

Sun, 24 Mar 2024
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $59.60 - Defense World

Fri, 22 Mar 2024
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade - Yahoo Finance

Wed, 13 Mar 2024
B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know - Markets Insider

Sat, 02 Mar 2024
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? - The Motley Fool

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 52 (M)
Shares Float 19 (M)
Held by Insiders 13.7 (%)
Held by Institutions 82.3 (%)
Shares Short 2,900 (K)
Shares Short P.Month 2,450 (K)
Stock Financials
EPS -1.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.44
Profit Margin 0 %
Operating Margin -655.8 %
Return on Assets (ttm) -12.3 %
Return on Equity (ttm) -17.6 %
Qtrly Rev. Growth -13.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.15
EBITDA (p.s.) -1.38
Qtrly Earnings Growth 0 %
Operating Cash Flow -51 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -28.53
PEG Ratio -0.3
Price to Book value 5.05
Price to Sales 240.71
Price to Cash Flow -38.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android